THE APEX TIMES
In a video update, Goldman Sachs Chief US Economist David Mericle ties the outlook to fading tariff, energy, and AI-related pressures, while cautioning that the Federal Reserve may still raise rates this December.
Goldman Sachs expects inflation to cool meaningfully over the next 14 months, projecting it will reach 2.4% by the end of 2027, according to commentary from the bank’s Chief US Economist David Mericle shared in a Yahoo Finance segment dated Nov. 20, 2026.
Mericle linked the forecast to a gradual easing of several forces that have been pushing prices higher, including tariff-related effects, energy price pressures, and demand or cost dynamics associated with artificial intelligence spending. The implication is that these factors are not expected to persist at the same intensity as the year progresses.
Even with that longer-run cooling view, Mericle said the Federal Reserve may still raise interest rates in December. The statement underscores a familiar policy tension for markets: inflation may be trending down, but the central bank could still consider additional tightening if incoming data do not fall in line with its target path.
The remarks also highlight how Wall Street’s macro outlook is increasingly split between medium-term normalization and near-term policy uncertainty. If inflation is forecast to be materially lower by late 2027, that can support a more stable rate environment later on. But a potential December hike suggests Goldman is not treating the decline as inevitable or immediate.
Goldman’s role as a major market participant means its inflation and rate path assumptions can influence broader expectations for borrowing costs and the trajectory of economic activity, even when those forecasts are not binding policy. For businesses and households, what matters is not only where inflation ends up in 2027, but how quickly it falls before the Fed’s next decisions.
What the segment did not provide in the information available here is additional detail on the specific inflation measure Goldman is using, the timing of projected month-by-month declines, or how its view changes under different scenarios such as renewed energy shocks or fresh tariff action. It also did not disclose any updated probability distribution around the Fed’s December decision beyond the general warning that another increase is possible.
As investors look ahead, the most immediate question raised by the commentary is whether inflation data between now and December will validate the “still possibly higher” message, or whether the easing forces Goldman cited will show up in price readings soon enough to reduce the need for additional tightening. Those data points are likely to drive the debate about the peak in policy rates and the pace of disinflation.
A market-focused note argues the company’s cash-return profile could matter as Wall Street debates whether 2027 can resemble 2022. The company, however, did not provide new disclosure in the cited post.
A market report said the U.S. Securities and Exchange Commission has opened an investigation involving Nvidia as the chipmaker absorbs fallout from a sharp selloff. Investors now have to parse what the agency is looking at and how much the matter could weigh on disclosures and governance.
A reported Phase 3 win for Moderna’s personalized melanoma therapy, used alongside Merck’s Keytruda, is prompting fresh optimism that the mRNA platform can expand beyond infectious disease. Still, key details such as magnitude of benefit and full trial disclosure remain to be validated.
Marques Brownlee said he has placed an order for Tesla’s Cybercab following a 2024 challenge, and Tesla CEO Elon Musk replied “fair enough,” saying he would accept delivery.
A new market read on Booz Allen Hamilton Holding points to a sizable gap between the company’s valuation and the cash flow the business can generate, sharpening questions for investors about how durable profits and cash generation are in the defense IT services market.
The company is pursuing Australian National Immunisation Program listings for its mRNA influenza vaccines after securing a March 2027 agenda spot with the PBAC, a key committee that advises public reimbursement.
A newly announced partnership between Microsoft and Danaher aims to pair AI-assisted capabilities with cloud-based scientific instruments and lab software, including early tools that are already moving toward commercial use.
A new market round-up from Yahoo Finance highlights how lingering discussion among Fed officials about whether interest rates need to rise again can reshape expectations for large, consumer-facing companies like PepsiCo.
The initiative, launched within Aetna, is designed to link a large share of expectant members and their newborns to coordinated maternal and infant care. CVS Health has not, in the reporting, disclosed staffing, clinical protocols, or outcome targets tied to the program.
A fresh round of holiday changes at Target centers on shopping hours and promotions, a shift the company is indicating as part of how it intends to drive demand into the end of the year.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...